An observational study in Adult Burkitt Lymphoma, Chemotherapy-Related Toxicity and Overall and Progression-Free Survival, sponsored by University Hospital, Strasbourg, France. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.
Sponsored by University Hospital, Strasbourg, France · Observational
Burkitt lymphoma is a rare, highly aggressive B-cell non-Hodgkin lymphoma in adults. Although intensive multi-agent chemotherapy can achieve high complete remission rates, it is associated with substantial toxicity, morbidity, and sometimes treatment-related mortality. This retrospective, single-center observational study aims to characterize the short- and long-term complications of intensive first-line treatment in adults with Burkitt lymphoma managed at Strasbourg University Hospitals.
The study will evaluate treatment-related toxicities, overall survival at five years, and progression-free survival at 24 months. Secondary objectives include assessing treatment delays, chemotherapy dose reductions, and their associations with toxicity, disease location at diagnosis, and survival.
All eligible adult patients diagnosed with Burkitt lymphoma or managed for this condition at Strasbourg University Hospitals and the ICANS between January 1, 2009, and December 31, 2025, will be considered. The study will use retrospective medical record data, with no a priori sample size calculation because of the rarity of the disease and the single-center design.
407 studies on the registry are indexed under Burkitt Lymphoma; 117 are open to participants now.
This study's planned enrollment of 25 is below the median of 203 across 27 observational studies indexed under Burkitt Lymphoma.
Browse Burkitt Lymphoma studies →University Hospital, Strasbourg, France is the lead sponsor of 994 studies on the registry; 353 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Adult patients with Burkitt lymphoma managed at Strasbourg University Hospitals and/or ICANS between January 1, 2009, and December 31, 2025, whose medical records are available and who meet the eligibility criteria
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Treatment-Related Toxicity
Incidence of different toxicities during intensive first-line treatment for adult Burkitt lymphoma
Time frame: Retrospective assessment of patients treated between January 1, 2009, and December 31, 2025
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Strasbourg, France →